The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.
In a three-year follow-up study, fewer than 2% of long COVID cases reported resolution of symptoms, with vaccinated patients demonstrating significantly better physical and mental health outcomes.
A large Ontario cohort study found that 1 in 5 adults treated in hospital for cannabis use were later diagnosed with dementia, with risk significantly higher than in the general population.
Individuals who reported a neutral level of satisfaction with their sense of belonging were approximately 3 times more likely to express an intent to leave, while those who were dissatisfied were 7 times more likely to do so, compared to individuals who were satisfied with their sense of belonging.
“There’s a chunk of workers that were lost and won’t come back”—five years post-COVID, staffing gaps are still reshaping patient care and physician workloads.